Institute of clinical pharmacology |
|
| |
> |
The Institute
of Clinical Pharmacology focuses
primarily upon the identification
of mechanisms involved in pain
and inflammation. Specific target
molecules, such as cyclooxygenases
(COX), nitric oxide (NO) synthases
or transcription factors (e.g.
NF-kappaB), as well as their
pharmacological manipulation,
are of special interest. The
goal is to establish a basic
understanding, which could lead
to the development of novel
and selective drugs.
The investigation of the anti-tumor
properties of analgesics contributes
to the characterization of their
impact on cancer therapy and
prophylaxis. This also contributes
to the identification of signaling
pathways of tumor manifestation.
Pharmacokinetic and pharmacodynamic
investigations of drug effects
and safety are carried out in
clinical trials by the Institute
of Clinical Pharmacology. Pharmacogenetic
studies are performed to explain
the variability of drug effects.
The drug transport in animals,
volunteers and patients can
be determined with the use of
microdialysis techniques in
combination with highly sensitive
detection methods (HPLC, GC,
LC/MS/MS) and mathematical models.
|
|
> |
Director:
- Prof. Dr. rer. nat. Dr.
med. Gerd Geißlinger
|
|
| |
| >
|
Staff:
- Prof. Dr. med. Sebastian
Harder (clinical trials, platelet
function and haemostasis)
- Prof. Dr. med.
Irmgard Tegeder
(molecular and
behavioral pain research)
- Prof. Dr. med. Jörn
Lötsch
(clinical trials, pharmakokinetic-pharmakodynamic
modelling, pharmakogenetics)
- Prof. Dr. rer.
nat. Rolf Nüsing(Pharmacology
of prostanoids, Nephrology)
- Dr. rer. nat. Sabine Grösch
(cell biology, anti-tumor
effects of analgesic drugs)
- Dr. rer. nat. Ellen Niederberger
(molecular biology, new targets
for the treatment of pain)
- Dr. phil. nat. Helmut Schmidt
(analytics)
- Dr. rer. nat. Klaus Scholich
(molecular biology, new targets
for the treatment of pain)
|
|
| |
|
|
|
|
